Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

PURPOSE: To improve survival rates in children with acute myeloid leukemia (AML), we evaluated gemtuzumab-ozogamicin (GO), a humanized immunoconjugate targeted against CD33, as an alternative to further chemotherapy dose escalation. Our primary objective was to determine whether adding GO to standar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gamis, Alan S., Alonzo, Todd A., Meshinchi, Soheil, Sung, Lillian, Gerbing, Robert B., Raimondi, Susana C., Hirsch, Betsy A., Kahwash, Samir B., Heerema-McKenney, Amy, Winter, Laura, Glick, Kathleen, Davies, Stella M., Byron, Patti, Smith, Franklin O., Aplenc, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4162498/
https://ncbi.nlm.nih.gov/pubmed/25092781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.55.3628
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados